Daniel Tillett
Fortune : 28 M $ au 31/07/2026
Fortune : 28 M $ au 31/07/2026
Dr. Daniel Tillett is a Chief Executive Officer, MD & Director at Racura Oncology Ltd. He is on the Board of Directors at Entropy Neurodynamics Ltd. and Racura Oncology Ltd. Dr. Tillett was previously employed as a Non-Executive Director by Simble Solutions Ltd., an Executive Director & Chief Scientific Officer by Race Oncology Ltd., and a Chief Executive Officer by Nucleics Ltd. He received his undergraduate degree from School of Biotechnology & Biomolecular Sciences and a doctorate degree from School of Biotechnology & Biomolecular Sciences.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RACURA ONCOLOGY LTD 10,34 % | 28/05/2026 | 20 269 351 ( 10,34 % ) | 28 M $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| RACURA ONCOLOGY LTD | Directeur Général | 22/11/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| SIMBLE SOLUTIONS LIMITED | Directeur/Membre du Conseil | 03/07/2023 |
| RACURA ONCOLOGY LTD | Directeur Technique/Scientifique/R&D | 23/03/2023 |
Nucleics Ltd. | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Race Oncology Ltd.
Race Oncology Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for cancer | Health Technology |
Simble Solutions Ltd.
Simble Solutions Ltd. Packaged SoftwareTechnology Services Develops software for enterprises to manage business and resources | Technology Services |
School of Biotechnology & Biomolecular Sciences
School of Biotechnology & Biomolecular Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nucleics Ltd. |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national